Advances in Myelofibrosis Treatment and Enhancing Patient Quality of Life : Episode 7

Adverse Events Seen With JAK Inhibitors for Myelofibrosis

January 31, 2024

By Christine Cooper, RN, BSN
Aaron T. Gerds, MD, MS

Opinion

Video

The JAK inhibitors approved for myelofibrosis have common side effects of cytopenias and gastrointestinal issues, with additional risks of weight gain and cardiac effects and diarrhea; momelotinib and pacritinib show improved tolerability compared to earlier JAK inhibitors.

EP: 1.Diagnosing Myelofibrosis

EP: 2.Assessing Risk Level of Patients With Myelofibrosis

EP: 3.Educational Resources for Patients Diagnosed With Myelofibrosis

EP: 4.Key Patient Goals for Myelofibrosis Management

EP: 5.Management of Anemia in Patients With Myelofibrosis

EP: 6.Clinical Data on the Approved JAK Inhibitors for Treatment of Myelofibrosis

EP: 7.Adverse Events Seen With JAK Inhibitors for Myelofibrosis

EP: 8.Assessing Treatment Response in Patients With Myelofibrosis

EP: 9.Best Approaches to Switching Therapies for a Patient With Myelofibrosis

EP: 10.Dosing JAK Inhibitors in Patients With Myelofibrosis

EP: 11.Key Takeaways for Patients With Myelofibrosis

Newsletter

Stay up to date on recent advances in oncology nursing and patient care.

Recent Videos

3 KOLs are featured in this series.

3 KOLs are featured in this series.

Image of a woman with blond hair wearing a headset and a hospital badge over a blouse in front of a watercolor Oncology Nursing News background

Latest Conference Coverage

The Reality of VTE: How to Best Address in Cancer Care

AI Decision Support Tools Serve as Copilots in Cancer Care

Toxicity Monitoring, Management Crucial for Tarlatamab in ES-SCLC

Cancer Drug Repository Network Yields $18M in Patient Savings

View More Latest Conference Coverage

Editorial Board

CancerNetwork.com

TargetedOnc.com

Terms & Conditions

Do Not Sell My Information

Contact Info

259 Prospect Plains Rd, Bldg H,
Cranbury, NJ 08512

© 2025 MJH Life Sciences

All rights reserved.